Biosig Technologies (NASDAQ:STEX) Shares Gap Up on Insider Buying Activity

Shares of Biosig Technologies, Inc. (NASDAQ:STEX) gapped up before the market opened on Wednesday after an insider bought additional shares in the company. The stock had previously closed at $3.65, but opened at $3.88. Biosig Technologies shares last traded at $3.76, with a volume of 1,599,808 shares traded.

Specifically, major shareholder Frank Giustra purchased 1,000,000 shares of Biosig Technologies stock in a transaction dated Friday, January 23rd. The stock was bought at an average price of $3.00 per share, with a total value of $3,000,000.00. Following the completion of the acquisition, the insider owned 1,178,205 shares in the company, valued at $3,534,615. The trade was a 561.15% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Morgan Lee Lekstrom acquired 23,000 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The stock was purchased at an average cost of $3.30 per share, for a total transaction of $75,900.00. Following the acquisition, the director owned 71,000 shares in the company, valued at approximately $234,300. This trade represents a 47.92% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In other news, Director Morgan Lee Lekstrom bought 41,000 shares of Biosig Technologies stock in a transaction on Friday, January 23rd. The stock was purchased at an average cost of $3.13 per share, with a total value of $128,330.00. Following the purchase, the director directly owned 48,000 shares of the company’s stock, valued at approximately $150,240. This trade represents a 585.71% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Analyst Ratings Changes

Separately, Weiss Ratings assumed coverage on Biosig Technologies in a report on Friday. They set a “sell (d-)” rating on the stock. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

More Biosig Technologies News

Here are the key news stories impacting Biosig Technologies this week:

• Positive Sentiment: Major shareholder Frank Giustra bought 1,000,000 shares at about $3.00 on Jan. 23, a large $3.0M purchase that signals strong insider conviction and can support the stock price. Read More.
• Positive Sentiment: CIO Mitchell Young Williams acquired 51,511 shares (~$3.03 each), increasing his holding to ~1.05M shares — another senior?management buy that reinforces confidence in the company’s outlook. Read More.
• Positive Sentiment: Director Morgan Lee Lekstrom executed several buys (41,000; 23,000; and 5,500 shares at roughly $3.13–$3.30), materially increasing her stake and adding to the pattern of insider accumulation. Read More.
• Neutral Sentiment: Press releases under the STEX ticker report closings of public offerings ($35M and $40.25M gross proceeds). If these relate to the same issuer, proceeds improve liquidity but imply recent share issuance that could dilute existing holders; if they reference a different issuer using the same ticker, they create market confusion. Read More.
• Negative Sentiment: Weiss Ratings initiated coverage with a “sell (d-)” and MarketBeat shows an average analyst view of “Sell” — negative third?party sentiment that can limit upside even amid insider buying. Read More.

Biosig Technologies Stock Performance

The stock has a market cap of $536.48 million, a PE ratio of -2.67 and a beta of 1.48.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.